Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy

Monday, April 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented by Pamart et al. at BSH 2024 discusses a novel method for isolating tumor-associated ctDNA fragments for liquid biopsy in acute myeloid leukemia (AML). This innovative approach aims to enhance prognostic capabilities and improve patient outcomes. The research highlights the potential of ctDNA analysis in cancer diagnostics.
Price reaction · baseline $17.402 (2024-04-29T16:51:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a novel liquid biopsy method for AML.
  • Potential for improved prognosis through ctDNA analysis.
  • Presentation at a significant conference (BSH 2024).

Full Press Release Details

Poster title: Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
Presented at BSH 2024
Pamart et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the poster presented at BSH 2024?

The poster focuses on a novel method for isolating tumor-associated ctDNA fragments for AML liquid biopsy.

Who presented the research on ctDNA for AML?

The research was presented by Pamart et al. at the BSH 2024 conference.

What is the significance of ctDNA analysis in cancer?

ctDNA analysis has the potential to improve prognostic capabilities in cancer diagnostics.

Where was the research on AML liquid biopsy presented?

The research was presented at the BSH 2024 conference.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare ctDNA liquid biopsy acute myeloid leukemia BSH 2024
Last updated: Apr 29, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk